Phibro Animal Health Corporation Reports First Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Phibro Animal Health Corporation Reports First Quarter

TEANECK, N.J., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Phibro Animal Health Corporation (Nasdaq: PAHC ) today announced its financial results for its first quarter ended September 30, 2014. It also updated guidance for its fiscal year ending June 30, 2015.

  • Highlights for the September 2014 quarter (compared to the September 2013 quarter)
    • Net sales of $187 million, an increase of 16%
    • Adjusted EBITDA of $30 million, an increase of 41%
    • Adjusted diluted EPS of $0.51
          
  • Guidance for the June 2015 fiscal year (compared to the June 2014 fiscal year) updated to reflect an increase of $4 million attributable to accelerated licensing revenue and profit for vaccine delivery technology.
    • Net sales of $739 - $759 million, representing growth of 7% - 10%
    • Adjusted EBITDA of $103 - $107 million, representing growth of 14% - 18%
    • Adjusted diluted EPS of $1.57 - $1.62

COMMENTARY

Commenting on the quarter, Jack Bendheim, Phibro's Chairman, President and Chief Executive Officer, said, "Our businesses delivered another solid quarter. Good volume growth across Animal Health and Mineral Nutrition was the key to the performance. We are also encouraged by the accelerated receipt of licensing revenue from our vaccine delivery technology."

QUARTERLY RESULTS

Net sales

Net sales of $187.5 million increased $25.2 million, or 16%, for the three months ended September 30, 2014, as compared to the three months ended September 30, 2013, due to growth in Animal Health and Mineral Nutrition of $16.1 million and $9.3 million, respectively. 

The consolidated statement of operations for the three months ended September 30, 2014 included $6.0 million of revenue and gross profit related to an existing license agreement with a global animal health company to share in the use of our proprietary vaccine delivery technology. We recognized the revenue and profit during the quarter because certain contractual and regulatory milestones were achieved by the licensee and we had no performance obligations under the agreement. Excluding the $6.0 million in licensing revenue, net sales growth was $19.2 million, or 12%.

Animal Health

Net sales of $117.2 million grew $16.1 million, or 16%, primarily due to volume growth across all product groups. Excluding the $6.0 million in revenue from the licensing agreement, net sales growth was $10.1 million, or 10%. Medicated Feed Additives ("MFAs") and other grew $2.8 million, or 4%, primarily due to volume growth in the Latin America and Asia Pacific regions. Nutritional specialty products grew $5.4 million, or 38%, primarily due to U.S. volume growth of our products for the dairy industry and their introduction in select European countries. Excluding the effect of the $6.0 million in licensing revenue, vaccines grew $1.9 million, or 20%, principally from volume growth.

Mineral Nutrition

Net sales of $55.4 million increased $9.3 million, or 20%. Increased volumes accounted for 74% of the sales growth resulting from current market conditions and customer demand for certain trace mineral products. 

Performance Products

Net sales of $14.8 million decreased $0.1 million, or 1%, due to lower average selling prices and lower volumes in personal care ingredients, partially offset by higher volumes of a low-margin industrial chemical. Lower average selling prices of copper-based products were offset by higher volumes. 

Gross profit

Gross profit of $60.3 million increased $10.8 million, or 22%, to 32.2% of net sales, with a majority of the improvement coming from Animal Health. Gross profit growth was $4.8 million, or 10%, excluding the effect of the $6.0 million in licensing revenue. Animal Health gross profit increased $3.7 million, excluding the effect of the licensing revenue, with approximately $4.2 million due to volume growth and favorable product mix and $0.6 million due to higher average selling prices and other items, partially offset by $1.1 million of higher product costs. MFAs and other contributed $0.2 million of the increase due to volume growth and average selling prices, partially offset by higher unit costs. Nutritional specialty products contributed $2.9 million of the increase primarily due to volume growth, higher average selling prices and lower unit costs. Excluding the current period gross profit from the licensing revenue for the vaccine delivery technology, vaccines gross profit increased $0.5 million principally due to volume growth. Mineral Nutrition gross profit increased $1.0 million due to higher average selling prices and higher volumes. Performance Products gross profit increased $0.1 million due to lower product costs and higher volumes, partially offset by lower average selling prices.

Selling, general and administrative expenses

Selling, general and administrative ("SG&A") expenses of $35.2 million increased $2.1 million, or 6%. Animal Health accounted for $1.5 million of the increase, driven by sales and marketing and development spending. Selling headcount and related marketing support increased in Brazil, Mexico and China to support MFA and vaccine initiatives and in the U.S. and Europe to support the expansion of our products to the dairy industry. Development spending focused on product lifecycle extensions. Corporate expenses increased $0.5 million due to increases in salary and wage related costs and professional fees, in part related to the costs of being a public company.

Adjusted EBITDA

Adjusted EBITDA of $30.5 million increased $8.9 million, or 41%. Adjusted EBITDA growth was $2.9 million, or 13%, excluding the $6.0 million in revenue from the licensing agreement. Animal Health adjusted EBITDA increased $2.3 million, or 10%, excluding the effect of the licensing revenue, due to sales growth and increased gross profit, partially offset by increased SG&A expenses. Mineral Nutrition increased $1.0 million, or 41%, due to higher sales volumes and improved operating margins. Performance Products decreased $0.1 million, or 5%. Corporate expense increased $0.4 million due to increases in salary and wage related costs and professional fees, in part related to the costs of being a public company.

Interest expense, net

Interest expense, net of $3.5 million decreased $5.2 million due to the net result of issuing the Term B Loan and Revolving Credit Facility in April 2014, retiring the Mayflower Term Loan, the BFI Term Loan and the Domestic Senior Credit Facility in April 2014 and redeeming the 9.25% Senior Notes in May 2014.

Foreign currency (gains) losses, net

Foreign currency (gains) losses, net for the three months ended September 30, 2014, amounted to net gains of $1.2 million, as compared to $0.6 million in net losses for the three months ended September 30, 2013. Foreign currency gains in the current period were primarily due to the movement of Brazil, Turkey and Belgium currencies relative to the U.S. dollar. Foreign currency gains and losses primarily arise from intercompany balances.

Provision for income taxes

Income taxes of $2.3 million were recorded on consolidated pre-tax income of $22.8 million, a 10.2% effective tax rate. The tax provision is comprised primarily of income taxes relating to profitable foreign jurisdictions, partially offset by a $1.2 million benefit from the recognition of certain previously unrecognized tax benefits. The provision for income taxes on domestic pre-tax income was substantially offset by the release of a valuation allowance previously recorded on accumulated domestic net operating losses.

Adjusted diluted EPS

Adjusted diluted EPS was $0.51 for the quarter, compared with $0.30 last year on a pro forma adjusted basis. The pro forma adjustments to last year reflect the effects of our initial public offering and refinancing. The pro forma adjustments assume the refinancing occurred at the beginning of the period, resulting in a reduction in annual interest expense of more than $19 million compared with historical levels. The pro forma adjustments also assume the additional common shares were outstanding for all periods presented.

BALANCE SHEET AND CASH FLOWS

  • 2.9x leverage ratio at September 30, 2014
    • $289 million total debt
    • $99.5 million LTM adjusted EBITDA
  • $20 million cash on hand at September 30, 2014
  • $13 million net cash flow before financing for the quarter
  • Financing activities
    • $3.9 million quarterly dividend paid
    • $0.9 million scheduled debt reduction

FINANCIAL GUIDANCE

We have increased our FY2015 guidance for the benefit of an additional $4 million of licensing revenue and profit for vaccine delivery technology. The revenue was recognized due to the accelerated achievement of a regulatory milestone under an existing license agreement that previously had been expected to occur in our FY2016. The increase benefits sales and adjusted EBITDA in equal amounts. Our guidance continues to contemplate an additional $2 million in licensing revenue and profit to be received later this fiscal year with the final milestone payment to be made under the license agreement, bringing the expected total licensing revenue and profit for the fiscal year to $8 million.

WEBCAST & CONFERENCE CALL DETAILS

Phibro Animal Health Corporation will host a webcast and conference call at 9:00 AM (EST) on Wednesday, November 12, 2014, during which the company will review fourth quarter and fiscal year 2014 financial results and respond to questions. Investors and the public may access the live webcast by visiting the Phibro website at http://investors.pahc.com .  A replay of the webcast will be archived and made available on Phibro's website until approximately February 15, 2015.

DISCLOSURE NOTICES

Forward-Looking Statements: This communication contains forward-looking statements, which reflect Phibro's current views with respect to business plans or prospects, future operating or financial performance, expectations regarding future use of cash and dividend payments, and other future events. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "aim," "anticipate," "believe," "estimate," "expect," "forecast," "outlook," "potential," "project," "projection," "plan," "intend," "seek," "believe," "may," "could," "would," "will," "should," "can," "can have," "likely," the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q, including in the sections thereof captioned "Forward-Looking Statements" and "Risk Factors." These filings and subsequent filings are available online at www.sec.gov , www.pahc.com , or on request from Phibro.

Non-GAAP Financial Information: We use non-GAAP financial measures, such as adjusted EBITDA, adjusted net income and pro forma adjusted diluted earnings per share, to assess and analyze our operational results and trends and to make financial and operational decisions. Management uses adjusted EBITDA as its primary operating measure. We report Adjusted Net Income to portray the results of our operations prior to considering certain income statement elements. We report pro forma adjusted diluted earnings per share to reflect the pro forma effects of the IPO and refinancing on all periods presented. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this communication should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this communication and/or our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q.

Internet Posting of Information: We routinely post information that may be important to investors in the "Investors" section of our website at www.pahc.com . We encourage investors and potential investors to consult our website regularly for important information about us.

         
Phibro Animal Health Corporation 
Consolidated Results of Operations
         
  Three Months 
For the Periods Ended September 30 2014 2013 Change
  (in millions, except per share amounts)
         
Net sales  $ 187.5  $ 162.2  $ 25.2 16%
Gross profit  60.3  49.5  10.8 22%
Selling, general and administrative expenses  35.2  33.1  2.1 6%
Operating income  $ 25.1  $ 16.4  $ 8.7 53%
Interest expense, net  3.5  8.7  (5.2) (60)%
Foreign currency (gains) losses, net  (1.2)  0.6  (1.9) *
Income before income taxes  $ 22.8  $ 7.0  $ 15.8 225%
Provision for income taxes  2.3  1.2  1.2 100%
Net income  $ 20.5  $ 5.8  $ 14.6 251%
         
Net income per share         
basic $0.53 $0.19    
diluted $0.52 $0.19    
         
Weighted average common shares outstanding       
basic  38.9  30.5    
diluted  39.6  30.5    
         
Ratio to net sales        
Gross profit 32.2% 30.5%    
Selling, general and administrative expenses 18.8% 20.4%    
Operating income 13.4% 10.1%    
Income before income taxes 12.2% 4.3%    
Net income 10.9% 3.6%    
Effective tax rate 10.2% 16.7%    
         
Amounts and percentages may reflect rounding adjustments    
* Calculation not meaningful        
         
         
Phibro Animal Health Corporation 
Segment Net Sales and Adjusted EBITDA
         
  Three Months 
For the Periods Ended September 30 2014 2013 Change
  (in millions)
Net Sales        
MFAs and other  $ 80.8  $ 78.0  $ 2.8 4%
Nutritional specialties  19.5  14.1  5.4 38%
Vaccines  16.9  9.1  7.9 87%
Animal Health  117.2  101.2  16.1 16%
Mineral Nutrition  55.4  46.2  9.3 20%
Performance Products  14.8  14.9  (0.1) (1)%
Total  $ 187.5  $ 162.2  $ 25.2 16%
         
Adjusted EBITDA        
Animal Health  $ 32.5  $ 24.1  $ 8.3 35%
Mineral Nutrition  3.5  2.5  1.0 41%
Performance Products  1.0  1.1  (0.1) (5)%
Corporate  (6.5)  (6.1)  (0.4) *
Total  $ 30.5  $ 21.6  $ 8.9 41%
         
Adjusted EBITDA ratio to segment net sales        
Animal Health 27.7% 23.8%    
Mineral Nutrition 6.3% 5.3%    
Performance Products 7.0% 7.4%    
Corporate (1) (3.5)% (3.7)%    
Total (1) 16.2% 13.3%    
(1) reflects ratio to total net sales        
         
         
Reconciliation of GAAP Net Income to Adjusted EBITDA
Net income  $ 20.5  $ 5.8  $ 14.6 251%
Interest expense, net  3.5  8.7  (5.2) (60)%
Provision for income taxes  2.3  1.2  1.2 100%
Depreciation and amortization  5.4  5.2  0.2 3%
EBITDA  31.7  21.0  10.7 51%
Foreign currency (gains) losses, net  (1.2)  0.6  (1.9) *
Adjusted EBITDA  $ 30.5  $ 21.6  $ 8.9 41%
         
Amounts and percentages may reflect rounding adjustments
* Calculation not meaningful
             
             
Phibro Animal Health Corporation 
Adjusted Net Income
             
  Three Months
  As Reported Adjustments  Adjusted
For the Periods Ended September 30 2014 2013 2014 2013 (1) 2014 2013 (1)
  (in millions, except per share amounts)
             
Net sales $187.5 $162.2  $ --   $ --  $187.5 $162.2
Gross profit  60.3  49.5  --   --   60.3  49.5
Selling, general and administrative expenses (2)  35.2  33.1  (1.1)  (1.4)  34.2  31.7
Operating income  25.1  16.4  1.1  1.4  26.2  17.8
Interest expense, net  3.5  8.7  --   (5.3)  3.5  3.4
Foreign currency (gains) losses, net  (1.2)  0.6  1.2  (0.6)  --   -- 
Income before income taxes  22.8  7.0  (0.1)  7.3  22.7  14.4
Provision for income taxes (3)  2.3  1.2  0.1  1.4  2.4  2.6
Net income  $ 20.5  $ 5.8  $ (0.2)  $ 5.9  $ 20.2  $ 11.8
             
Net income per share - diluted  $ 0.52  $ 0.19      $ 0.51  $ 0.30
             
Weighted average common shares outstanding - diluted (4)  39.6  30.5      39.6  39.5
             
(1) 2013 includes pro forma adjustments to reflect the effects of our initial public offering and refinancing.
(2) Adjustments to selling, general and administrative expense include intangible amortization of $1.1 and $1.3 and stock-based compensation of $0.0 and less than $0.1 for 2014 and 2013, respectively.
(3) We adjust the provision for income taxes to reflect cash income taxes paid in the period.
(4) Prior year weighted average diluted shares are pro forma for our IPO and are based on a $19.01 market price, equal to the average for April 11-June 30, 2014.
       
       
Phibro Animal Health Corporation 
Operating and Investing Cash Flows
       
  Three Months 
For the Periods Ended September 30 2014 2013 Change
  (in millions)
       
Adjusted EBITDA  $ 30.5  $ 21.6  $ 8.9
Interest paid  (3.3)  (15.3)  12.0
Income taxes paid  (2.4)  (2.6)  0.1
Changes in operating assets and liabilities and other items  (7.4)  (3.9)  (3.5)
Net cash provided (used) by operating activities  $ 17.4  $ (0.2)  $ 17.6
       
Capital expenditures  $ (4.0)  $ (4.2)  $ 0.2
Net cash provided (used) by investing activities  $ (4.0)  $ (4.2)  $ 0.3
       
Net cash flow before financing activities  $ 13.4  $ (4.4)  $ 17.8

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy and aquaculture. For further information, please visit www.pahc.com .

Phibro Animal Health Corporation Richard Johnson Chief Financial Officer 201-329-7300 or

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 86

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 152

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 91

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 89

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 18

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 61

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
OCEG Faces China's Demographic Test After 40 Years

Updated Category News Views 44

A school group that once opened 35 kindergartens in a year is admitting the old playbook has run its course. That is the real message behind Oriental Cambridge Education Group's 40th-anniversary talk, not the balloons and ceremonial language. OCEG operates more than 170 institutions across 39 Chinese cities, and its chairman, Yu Yue, says the next chapter will be judged...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 162

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 64

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 87

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading

Top 5 Most Recently Viewed Articles

Uptown Cheapskate and Kid to Kid Shaping the Resale Future

Updated Category News Views 413

Innovating the Resale Landscape with Uptown Cheapskate and Kid to Kid BaseCamp Franchising is witnessing a remarkable transformation in the retail sector through its brands, Uptown Cheapskate and Kid to Kid. With over 260 stores across various U.S. states and additional international locations, these brands are redefining thrift shopping by merging the thrill of the hunt...

Continue Reading
Midea's Indoor Hybrid Heat Pump Revolutionizes Home Heating

Updated Category News Views 348

Midea’s Innovative CirQHP Indoor Hybrid Heat Pump Midea, a well-known leader in the HVAC industry, has unveiled its latest creation: the CirQHP Indoor Hybrid heat pump. This cutting-edge system has been honored with the Innovative Heating Technology Gold Award at an international exhibition. The CirQHP Indoor Hybrid allows homeowners to enjoy a modern heating solution...

Continue Reading
Exploring NYC's Future Guaranteed Income Program for Residents

Updated Category News Views 168

New York City’s Guaranteed Income Initiative New York City is embarking on a transformative journey to introduce a guaranteed income program aimed at helping those in need. Planned for 2026, this program will distribute $15,800 annually to residents who are facing economic hardships. It's an innovative approach to addressing poverty and housing insecurity within the...

Continue Reading
Investigating Potential Shareholder Dilemmas for TXNM, STRR, PVBC

Updated Category News Views 145

Understanding Shareholder Rights and Legal Investigations In the evolving landscape of corporate mergers and acquisitions, shareholder rights play a crucial role. Many companies are involved in significant transactions that raise questions for their shareholders. Today, we explore multiple companies undergoing scrutiny due to potential violations related to shareholder...

Continue Reading
Legal Battle Unfolds as U.S. Steel and Nippon Steel Challenge Biden

Updated Category News Views 215

U.S. Steel and Nippon Steel Challenge Government Actions United States Steel Corp (NYSE: X) and Nippon Steel Corp have taken significant legal steps against the Biden administration after the President's decision to block their ambitious $14.9 billion merger. This action by the government has raised questions about the motivations behind the blockade. The Legal Actions...

Continue Reading